Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $95.22 million. The enterprise value is $337.06 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 63.48 million shares outstanding. The number of shares has decreased by -0.18% in one year.
| Current Share Class | 63.48M |
| Shares Outstanding | 63.48M |
| Shares Change (YoY) | -0.18% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 15.21% |
| Float | 33.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.30 |
| Forward PS | 0.38 |
| PB Ratio | 0.37 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 1.76 |
| P/OCF Ratio | 1.61 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 28.54, with an EV/FCF ratio of 6.23.
| EV / Earnings | n/a |
| EV / Sales | 1.06 |
| EV / EBITDA | 28.54 |
| EV / EBIT | n/a |
| EV / FCF | 6.23 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.90.
| Current Ratio | 0.94 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | 15.08 |
| Debt / FCF | 4.78 |
| Interest Coverage | -0.17 |
Financial Efficiency
Return on equity (ROE) is -18.95% and return on invested capital (ROIC) is -0.53%.
| Return on Equity (ROE) | -18.95% |
| Return on Assets (ROA) | -0.39% |
| Return on Invested Capital (ROIC) | -0.53% |
| Return on Capital Employed (ROCE) | -1.13% |
| Revenue Per Employee | $423,647 |
| Profits Per Employee | -$75,066 |
| Employee Count | 751 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.84 |
Taxes
In the past 12 months, BIOX has paid $4.62 million in taxes.
| Income Tax | 4.62M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.58% in the last 52 weeks. The beta is 0.45, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -77.58% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 3.37 |
| Relative Strength Index (RSI) | 42.42 |
| Average Volume (20 Days) | 438,448 |
Short Selling Information
| Short Interest | 963,095 |
| Short Previous Month | 926,526 |
| Short % of Shares Out | 1.52% |
| Short % of Float | 2.91% |
| Short Ratio (days to cover) | 0.81 |
Income Statement
In the last 12 months, BIOX had revenue of $318.16 million and -$56.37 million in losses. Loss per share was -$0.89.
| Revenue | 318.16M |
| Gross Profit | 125.43M |
| Operating Income | -4.91M |
| Pretax Income | -55.47M |
| Net Income | -56.37M |
| EBITDA | 11.81M |
| EBIT | -4.91M |
| Loss Per Share | -$0.89 |
Full Income StatementBalance Sheet
The company has $16.61 million in cash and $258.45 million in debt, giving a net cash position of -$241.84 million or -$3.81 per share.
| Cash & Cash Equivalents | 16.61M |
| Total Debt | 258.45M |
| Net Cash | -241.84M |
| Net Cash Per Share | -$3.81 |
| Equity (Book Value) | 288.33M |
| Book Value Per Share | 4.07 |
| Working Capital | -16.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $59.13 million and capital expenditures -$5.04 million, giving a free cash flow of $54.09 million.
| Operating Cash Flow | 59.13M |
| Capital Expenditures | -5.04M |
| Free Cash Flow | 54.09M |
| FCF Per Share | $0.85 |
Full Cash Flow StatementMargins
Gross margin is 39.42%, with operating and profit margins of -1.54% and -17.72%.
| Gross Margin | 39.42% |
| Operating Margin | -1.54% |
| Pretax Margin | -17.44% |
| Profit Margin | -17.72% |
| EBITDA Margin | 3.71% |
| EBIT Margin | -1.54% |
| FCF Margin | 17.00% |
Dividends & Yields
BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.18% |
| Shareholder Yield | 0.18% |
| Earnings Yield | -59.21% |
| FCF Yield | 56.81% |
Analyst Forecast
The average price target for BIOX is $4.42, which is 194.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.42 |
| Price Target Difference | 194.67% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BIOX has an Altman Z-Score of 0.66 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.66 |
| Piotroski F-Score | 3 |